Long-term nicotine replacement therapy: A randomized clinical trial

JAMA Internal Medicine

Volumn 175, Issue 4, 2015, Pages 504-511

  Schnoll, Robert A ^a   Goelz, Patricia M ^b   Veluz Wilkins, Anna ^c   Blazekovic, Sonja ^a   Powers, Lindsay ^c   Leone, Frank T ^d   Gariti, Peter ^a   Wileyto, E Paul ^e   Hitsman, Brian ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b National Comprehensive Cancer Network   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NICOTINE PATCH; NICOTINE; NICOTINE GUM;

ABNORMAL DREAMING; ADULT; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; EPIPHORA; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; INSOMNIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PATIENT COUNSELING; PHYSICAL DISABILITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN REDNESS; SMOKING CESSATION; STUDY DESIGN; TREATMENT DURATION; VOMITING; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CUTANEOUS DRUG ADMINISTRATION; DIRECTIVE COUNSELING; PREVENTION AND CONTROL; PROCEDURES; RECURRENT DISEASE; SELF REPORT; SMOKING; THERAPY; TREATMENT OUTCOME; UTILIZATION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; DIRECTIVE COUNSELING; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; RECURRENCE; SELF REPORT; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84928200598     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.8313     Document Type: Article

References (21)

1. Fix BV, Hyland A, Rivard C, et al. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health. 2011;8(1):222-233.
2. Kasza KA, Hyland AJ, Borland R, et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2013;108(1):193-202.
3. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102-111.
4. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Public Health Service; 2008. US Public Health Service Clinical Practice Guideline.
5. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
6. Carpenter MJ, Jardin BF, Burris JL, et al. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs. 2013;73(5):407-426.
7. Schnoll RA, Patterson F, Wileyto EP, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010;152(3):144-151.
8. Fucito LM, Bars MP, Forray A, et al. Addressing the evidence for FDA nicotine replacement therapy label changes: a policy statement of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Nicotine Tob Res. 2014;16(7):909-914.
9. Joseph AM, Fu SS, Lindgren B, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. Arch Intern Med. 2011;171(21):1894-1900.
10. Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009;104(6):1043-1052.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. ed 4. Washington, DC: American Psychiatric Association; 1994.
12. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
13. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
14. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1):6-11.
15. Brown R, Burgess E, Sales S, Whiteley J. Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav. 1998;12(2):101-112.
16. Goelz PM, Audrain-McGovern JE, Hitsman B, et al. The association between changes in alternative reinforcers and short-term smoking cessation. Drug Alcohol Depend. 2014;138:67-74.
17. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149-159.
18. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25.
19. Mooney M, White T, Hatsukami D. The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials. Addict Behav. 2004;29(4):673-684.
20. Schnoll RA, Epstein L, Audrain J, et al. Can the blind see? participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. J Subst Abuse Treat. 2008;34(2):234-241.
21. Shiffman S, Sweeney CT, Ferguson SG, Sembower MA, Gitchell JG. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clin Ther. 2008;30(10):1852-1858.